- Home
- IRON
IRON
Disc Medicine Inc.
as 05-09-2025 12:38pm EST
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $83.80 | AVG Volume (30 days): | 405.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.25 - $68.73 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Disc Medicine Inc. (IRON)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Savage William Jacob | IRON | Chief Medical Officer | May 2 '25 | Sell | $50.17 | 2,100 | $105,367.08 | 66,398 | |
| ORBIMED ADVISORS LLC | IRON | Director | Mar 24 '25 | Sell | $54.11 | 5,738 | $310,483.18 | 482,308 | |
| Ashiya Mona | IRON | Director | Mar 24 '25 | Sell | $54.11 | 5,738 | $310,483.18 | 746,171 | |
| ORBIMED ADVISORS LLC | IRON | Director | Mar 19 '25 | Sell | $54.01 | 52,429 | $2,831,986.74 | 482,308 | |
| Ashiya Mona | IRON | Director | Mar 19 '25 | Sell | $54.01 | 52,429 | $2,831,986.74 | 746,171 | |
| ORBIMED ADVISORS LLC | IRON | Director | Mar 10 '25 | Sell | $54.56 | 312,384 | $16,965,596.07 | 482,308 | |
| Ashiya Mona | IRON | Director | Mar 10 '25 | Sell | $54.56 | 312,384 | $16,965,596.07 | 746,171 | |
| Quisel John D | IRON | Chief Executive Officer | Feb 18 '25 | Sell | $54.58 | 5,574 | $304,228.92 | 154,828 | |
| Stephenson Pamela | IRON | Chief Commercial Officer | Feb 18 '25 | Sell | $54.58 | 3,137 | $171,217.46 | 69,529 | |
| Franchi Jean M. | IRON | Chief Financial Officer | Feb 18 '25 | Sell | $54.58 | 3,136 | $171,162.88 | 69,530 |
Latest Disc Medicine Inc. News
IRON Breaking Stock News: Dive into IRON Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Here's Why We're Not Too Worried About Disc Medicine's (NASDAQ:IRON) Cash Burn Situation
GlobeNewswire
2 days ago
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
10 days ago
Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)
Insider Monkey
a month ago
Is Disc Medicine, Inc. (NASDAQ:IRON) the Best Small Cap Stock to Buy Before They Explode?
MT Newswires
2 months ago
Disc Medicine Insider Sold Shares Worth $2,831,987, According to a Recent SEC Filing
Simply Wall St.
2 months ago
With 65% ownership, Disc Medicine, Inc. (NASDAQ:IRON) boasts of strong institutional backing
Barrons.com
2 months ago
Victoria’s Secret, Bitdeer, and More Stocks See Activist Action
Zacks
2 months ago
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
Compare IRON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRON Disc Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.